Immunovaccine to Present at Ninth Annual Immunotherapies and Vaccines Summit (ImVacS) Conference

HALIFAX, NOVA SCOTIA--(Marketwired - Aug. 12, 2014) - Immunovaccine Inc. ("Immunovaccine" or "IMV") (TSX VENTURE:IMV), a clinical stage vaccine company, announced today that Marc Mansour, Ph.D., the Company's chief executive officer, will make a presentation at the Ninth Annual Immunotherapies and Vaccines Summit (ImVacS). In addition to his presentation, Dr. Mansour will also serve as chairperson of the conference's "Clinical Updates of Combination Immunotherapies" session. The conference will take place on August 11-14, 2014 at the Marriott Long Wharf Hotel in Boston, MA.

Dr. Mansour's presentation will describe the clinical and immunological activity observed with the Company's cancer therapy DPX-Survivac. The robust and persistent T cell responses achieved in a majority of patients will be detailed. Dr. Mansour will also discuss preclinical results describing the synergy of a DepoVax^™-based vaccine with an anti-PD-1 checkpoint inhibitor to enable stronger anti-tumor activity and induce tumor regression.

Specific details of Dr. Mansour's presentation are as follows:

About DPX-Survivac

DPX-Survivac consists of survivin-based peptide antigens formulated in the DepoVax^™ adjuvanting platform. Survivin has been recognized by the National Cancer Institute (NCI) as a promising tumor-associated antigen (TAA) because of its therapeutic potential and its cancer specificity. Survivin is broadly over-expressed in solid tumors and blood cancers including ovarian, breast, colon and lung cancers, among others. Survivin plays an essential role in antagonizing apoptosis, supporting tumor-associated angiogenesis, and promoting resistance to various anti-cancer therapies. Survivin is also a prognostic factor for many cancers and it is found in high percentage of cancer patients.

The DPX-Survivac vaccine is thought to work by eliciting a cytotoxic T cell immune response against cells presenting survivin peptides on HLA class I molecules. This targeted therapy attempts to use the immune system to actively search for tumor cells expressing survivin and destroy them.

About Immunovaccine

Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company's DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase I human clinical trials. Lead cancer vaccine therapy, DPX-Survivac, is expected to enter Phase II clinical studies in both ovarian cancer and glioblastoma (brain cancer). The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV) and anthrax. Connect at www.imvaccine.com.

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future, including information regarding the use of proceeds of the financing, is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.